Inhibition of 5-LO activity in several breast cancer cell lines also resulted in growth inhibition and enhanced apoptosis, but 5-LO inhibitors have not yet been evaluated in clinical trials in breast cancer patients (Avis et al. 2001). Here, ALOX5 is linked to breast carcinoma.